Search

everythinglearnresearchcommunity

for

Search:↓

User shared before and after photos of hair regrowth using Dutasteride 5x a week for 19 months. They experienced significant improvement and thanked others for their support.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

, you can find it online with a script This user was discussing their progress with hair loss treatments including 5mg oral Minoxidil and combining 3mg oral Minoxidil with MTF HRT. They also discussed side effects of increased body hair in other parts of the body.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

The user reported significant hair regrowth using a topical treatment of 0.3% finasteride and 6% minoxidil, with noticeable progress in five months. The treatment is applied once daily, and the user experienced some initial shedding but no side effects.

The conversation discusses using GHK-Cu, C60, and saw palmetto oil as treatments for hair loss. Specific treatments mentioned include Minoxidil (Min), Finasteride (Fin), and RU58841 (RU).

The conversation concludes that finasteride, a 5α-Reductase inhibitor used for hair loss, does not impair cognition either short-term or long-term. It suggests "brain fog" is not caused by the medication.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

The user experienced significant hair regrowth and reduced shedding after increasing their dosage of minoxidil to 5mg daily and finasteride to 5mg three times a week. They reported noticeable improvements within five months and encouraged others to consider this treatment.

The user is inquiring about alternating daily doses of Minoxidil, taking 5mg one day and 2.5mg the next. They are seeking advice on whether this dosing schedule is acceptable.

A 25-year-old male experienced noticeable temple regrowth using 1mg finasteride, 2.5mg oral minoxidil, and 2mg GHK-Cu over three months. The user is pleased with the progress, especially on the left temple.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

The user is considering starting oral minoxidil for hair regrowth, debating between 2.5mg and 5mg doses, while already using topical minoxidil, dutasteride, and ketoconazole shampoo. Users suggest starting with a lower dose to monitor side effects, with some recommending trying finasteride first.

A 25-year-old with aggressive diffuse NW5 hair loss is using Minoxidil, oral Finasteride, RU58841, Ketoconazole, and dermastamping, experiencing slow progress and mental health struggles. Despite some visible regrowth, the user feels discouraged due to ongoing hair loss and is seeking reassurance and advice.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

Capilia Longa is considered as an alternative to Minoxidil for beard growth, with some users reporting positive results. However, concerns exist about its effectiveness and high cost, especially for scalp use.

The user has been using oral finasteride and topical minoxidil for 5 years, which stopped diffuse thinning but did not improve the hairline. They are considering a hair transplant and possibly starting dutasteride.

The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.

Minoxidil and caffeine are discussed for hair loss treatment. The user questions the logic of combining them due to their opposing effects on adenosine receptors.

A 19-year-old male switched from finasteride and minoxidil to dutasteride due to continued hair thinning and is experiencing increased nipple sensitivity and a small lump, raising concerns about gynecomastia. Suggestions include slowing the transition, checking hormone levels, and considering an aromatase inhibitor.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

Exploring treatment options for male pattern baldness, including minoxidil, finasteride, and RU58841, with a focus on Eucapil, a topical agent. The post also discusses research from various sources about the efficacy of these treatments.

A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

The conversation discusses a topical formula for hair loss including Finasteride (0.025%), Minoxidil (0.5%), Tretinoin (0.01%), Caffeine (0.005%), Melatonin (0.003%), Tea Tree Oil (0.05%), Aloe (0.05%), Biotin (0.05%), and Fagron TrichoXidil (2.5%). The user considers removing Minoxidil and Tretinoin to test TrichoXidil's effectiveness.

User mixed RU58841 with stemoxydine, experienced no side effects. Mixing RU58841 with fluridil caused chest tightness.

RU58841 treatment for hair loss, comparing premixed solutions to powder form. Users prefer powder for cost-effectiveness and customization.

The user is concerned about patchy hair regrowth after 5.5 months of treatment. They are questioning if more hair growth can be expected in the upcoming months.